Cargando…
Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial
BACKGROUND: Tiotropium via the HandiHaler device is an established long-acting, anticholinergic bronchodilator that prevents exacerbations and improves lung function in patients with chronic obstructive pulmonary disease. We hypothesised that tiotropium would reduce pulmonary exacerbations and impro...
Autores principales: | Jayaram, Lata, Vandal, Alain C., Chang, Catherina L., Lewis, Chris, Tong, Cecilia, Tuffery, Christine, Bell, Jill, Fergusson, Wendy, Jeon, Gene, Milne, David, Jones, Stuart, Karalus, Noel, Hotu, Sandra, Wong, Conroy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178212/ https://www.ncbi.nlm.nih.gov/pubmed/34795034 http://dx.doi.org/10.1183/13993003.02184-2021 |
Ejemplares similares
-
Vitamin D(3) supplementation in adults with bronchiectasis: A pilot study
por: Bartley, Jim, et al.
Publicado: (2018) -
Neurological and Sleep Disturbances in Bronchiectasis
por: Phua, Chun Seng, et al.
Publicado: (2017) -
Sputum procalcitonin: a potential biomarker in stable bronchiectasis
por: Good, William, et al.
Publicado: (2021) -
Bronchiectasis in the Last Five Years: New Developments
por: Khoo, Jun Keng, et al.
Publicado: (2016) -
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
por: Muruganandan, Sanjeevan, et al.
Publicado: (2015)